| Lutetium (177lu) lilotomab satetraxetan | 177Lu-DOTA-HH1 | Phase 2 Clinical | Nordic Nanovector | Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | 詳細 |
| DS-3790a | DS3790a; DS-3790a | Phase 2 Clinical | Daiichi Sankyo Co Ltd | | 詳細 |
| Naratuximab emtansine | IMGN-529; K7153A-SMCC-DM1 | Phase 2 Clinical | Immunogen Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | 詳細 |
| Debio-1562M | Debio-1562M | Phase 2 Clinical | Debiopharm International Sa | Leukemia, Myeloid, Acute; Neoplasms | 詳細 |
| AGS-67E | AGS-67E | Phase 1 Clinical | Agensys Inc | Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | 詳細 |
| CAR-37 T cell therapy (Massachusetts General Hospital) | | Phase 1 Clinical | Massachusetts General Hospital | Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | 詳細 |
| CAR-37 T cells(The General Hospital) | | Phase 1 Clinical | The General Hospital Corporation D/B/A Massachusetts General Hospital | Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | 詳細 |
| anti-CD19 + anti-CD37 bispecific CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology) | | Clinical | Huazhong University Of Science And Technology | | 詳細 |
| DS3790 | DS-3790; DS3790 | Clinical | Daiichi Sankyo Inc | | 詳細 |